The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

III.a

Alveolar hemorrhage (AH), diffuse AH (DAH)

Publications

Jin SM, Yim JJ, Yoo CG, Kim YW, Han SK, Shim YS, Lee SM

Aetiologies and outcomes of diffuse alveolar haemorrhage presenting as acute respiratory failure of uncertain cause.

Respirology (Carlton, Vic.) 2009 Mar;14;290-4 — 2009 Mar — 290-4

Nagashima O, Tajima K, Ito J, Kajiyama Y, Shimanuki Y, Miura K, Sato K, Miyamoto H, Uekusa T, Suzuki T, Takahashi K, Fukuchi Y

[A case of non-small cell lung cancer accompanied with hemorrhage after chemotherapy including gemcitabine].

Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 2006 Mar;44;215-9 — 2006 Mar — 215-9

Carron PL, Cousin L, Caps T, Belle E, Pernet D, Neidhardt A, Capellier G

Gemcitabine-associated diffuse alveolar hemorrhage.

Intensive care medicine 2001 Sep;27;1554 — 2001 Sep — 1554

Pavlakis N, Bell DR, Millward MJ, Levi JA

Fatal pulmonary toxicity resulting from treatment with gemcitabine.

Cancer 1997 Jul 15;80;286-91 — 1997 Jul 15 — 286-91